Breaking News Headlines Today

News from Pharmacy Times

All of today’s top news stories from Pharmacy Times. Get the full analysis behind how media bias impacts breaking news.

We’ve discovered 678 headlines written by Pharmacy Times during the past 3 months.

Pharmacy Times’s media bias is unknown. Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check.

We’ve assigned a rating of Unknown factuality to Pharmacy Times. You can read more about how we’ve determined Pharmacy Times’s credibility and reliability as a news source here: https://groundnews.lakegeneva.lib.wi.us/rating-system.

Information about Pharmacy Times

Where is Pharmacy Times located?Pharmacy Times's Website

Media Bias Ratings

Do you diasgree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top Pharmacy Times News

Robert F. Kennedy Jr. · United States

US bans vaccine ingredient targeted by anti-vaxxers

64% Center coverage: 51 sources

The US health department said Wednesday it would end the use of a vaccine ingredient long targeted by conspiracy theorists over debunked claims it causes autism.See the Story

HIV · Amsterdam

EU regulator approves injectable HIV drug that experts say could help stop transmission

36% Right coverage: 25 sources

See the Story

Health

AI Platforms Produce Melanoma Vaccine Blueprint and Protein Binders for Targeted T-Cell Therapy

100% Center coverage: 8 sources

See the Story

HHS orders thimerosal out of all flu vaccines

Coverage: 2 sources

Open the article to view the coverage from STATRobert F. Kennedy Jr. · United States See the Story

FDA Rejects RP1 for Advanced Melanoma, Says IGNYTE Not a ‘Well-Controlled’ Trial

67% Center coverage: 3 sources

The FDA has issued a complete response letter to Replimune indicating it is unable to approve the biologics license application for vusolimogene oderparepvec in combination with nivolumab for the treatment of advanced melanoma.According to a company press release, the letter indicates that the FDA cannot approve the application for vusolimogene oderparepvec (RP1) — the company’s leadFDA · United States See the Story

Cuts to Federal Funding Threaten Clostridioides Difficile Research and Prevention Efforts

With cuts to the Department of Health and Human Services incoming, efforts to research, surveil, and prevent infections of Clostridioides difficile could be derailed.United States · United States Read Article

Global Landscape of RSV Outbreaks: Prevalence, Characteristics, and Trends

RSV outbreaks pose significant risks globally, highlighting the urgent need for targeted vaccination and treatment strategies to protect vulnerable populations.Vaccinations Read Article

Conference Recap: American Diabetes Association 85th Scientific Sessions

Pharmacy Times offers the latest news and insights for the pharmacy professional and solutions that impact the everyday practice of pharmacy.United States · United States Read Article

COVID-19 Pandemic Reduced Gaps in Pneumococcal Vaccination in Medicare Enrollees, But Lowered Overall Uptake

Conversely, Medicaid enrollees experienced widening gaps of pneumococcal vaccination uptake, likely driven by socioeconomic obstacles.United States · United States Read Article

Avatrombopag Receives FDA Approval for Treamtent of Pediatric Patients With Chronic Immune Thrompcytopenia

Avatrombopag gains FDA approval for pediatric ITP treatment, offering a new oral option for managing chronic thrombocytopenia in children.United States · United States See the Story

Transforming Pharmacy Operations at Ochsner Health Through AI

Ochsner partners with Latent Health to utilize clinical artificial intelligence (AI), speeding prior authorizations, improving pharmacy efficiency, and increasing patient access to medications.Artificial Intelligence · New Orleans See the Story

News from Pharmacy Times